CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 143 enrolled
Drug / intervention
ETC-1002 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02178098
NCT02178098Phase 2Completed
CompareCT.gov

A Placebo-Controlled, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia and Hypertension

Esperion Therapeutics, Inc.·interventional·Posted Jun 30, 2014·Updated Apr 4, 2023

In Brief

A Phase 2 clinical trial evaluating ETC-1002 and Placebo for Hypercholesterolemia and Hypertension. Completed, enrolled 143 participants across 43 sites.

Detailed Summary

This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in participants with hypercholesterolemia and hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia, Hypertension
CountriesUnited States
CollaboratorsMedpace, Inc.

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 30, 2014
Enrollment StartJun 16, 2014
Primary CompletionMay 22, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.0 years ago

Interventions

ETC-1002drug

ETC-1002 capsules taken once daily

Placebodrug

Placebo capsules taken once daily